Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status

Anaplastic thyroid cancer (ATC) is a rare refractory disease, frequently associated with BRAF mutations and aberrant vascular endothelial growth factor (VEGF) secretion. The antitumor effects of sorafenib were evaluated, and its mechanisms of action were investigated. Four human ATC cell lines were...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihara, Sae, Onoda, Naoyoshi, Noda, Satoru, Asano, Yuka, Tauchi, Yukie, Morisaki, Tamami, Kashiwagi, Shinichiro, Takashima, Tsutomu, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776193/
https://www.ncbi.nlm.nih.gov/pubmed/31545405
http://dx.doi.org/10.3892/ijo.2019.4881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776193/
https://www.ncbi.nlm.nih.gov/pubmed/31545405
http://dx.doi.org/10.3892/ijo.2019.4881

Ejemplares similares